• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

成本效益比的置信区间。

Confidence intervals for cost/effectiveness ratios.

作者信息

Wakker P, Klaassen M P

机构信息

Medical Decision Making Unit, University of Leiden, The Netherlands.

出版信息

Health Econ. 1995 Sep-Oct;4(5):373-81. doi: 10.1002/hec.4730040503.

DOI:10.1002/hec.4730040503
PMID:8563835
Abstract

The reduction of costs is becoming increasingly important in the medical field. The relevant topic of many clinical trials is not effectiveness per se, but rather cost-effectiveness ratios. Surprisingly, no statistical tools for analyzing cost-effectiveness ratios have been provided in the medical literature yet. This paper explains the gap in the literature, and provides a first technique for obtaining confidence intervals for cost-effectiveness ratios. The technique does not use sophisticated tools to achieve maximal optimality, but seeks for tractability and ease of application while still satisfying all formal statistical requirements.

摘要

成本降低在医学领域正变得越来越重要。许多临床试验的相关主题并非有效性本身,而是成本效益比。令人惊讶的是,医学文献中尚未提供用于分析成本效益比的统计工具。本文解释了文献中的这一空白,并提供了一种获取成本效益比置信区间的初步技术。该技术并非使用复杂工具来实现最大最优性,而是在满足所有正式统计要求的同时,寻求可处理性和易于应用。

相似文献

1
Confidence intervals for cost/effectiveness ratios.成本效益比的置信区间。
Health Econ. 1995 Sep-Oct;4(5):373-81. doi: 10.1002/hec.4730040503.
2
Trying to do better than average: a commentary on 'statistical inference for cost-effectiveness ratios'.力求超越平均水平:对“成本效益比的统计推断”的评论
Health Econ. 1997 Sep-Oct;6(5):491-5. doi: 10.1002/(sici)1099-1050(199709)6:5<491::aid-hec293>3.0.co;2-r.
3
Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data.从临床试验数据估计增量成本效益比时的样本量和检验效能问题。
Health Econ. 1999 May;8(3):203-11. doi: 10.1002/(sici)1099-1050(199905)8:3<203::aid-hec413>3.0.co;2-7.
4
Definition, interpretation and calculation of cost-effectiveness acceptability curves.成本效益可接受性曲线的定义、解释与计算
Health Econ. 2000 Oct;9(7):623-30. doi: 10.1002/1099-1050(200010)9:7<623::aid-hec539>3.0.co;2-v.
5
In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care.探寻力量与意义:医疗保健领域随机成本效益研究的设计与分析问题
Med Care. 1994 Feb;32(2):150-63. doi: 10.1097/00005650-199402000-00006.
6
Statistical inference for cost-effectiveness ratios.成本效益比的统计推断。
Health Econ. 1997 May-Jun;6(3):229-42. doi: 10.1002/(sici)1099-1050(199705)6:3<229::aid-hec268>3.0.co;2-m.
7
Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane.置信区间还是曲面?成本效益平面上的不确定性。
Health Econ. 1998 Dec;7(8):723-40. doi: 10.1002/(sici)1099-1050(199812)7:8<723::aid-hec392>3.0.co;2-o.
8
The usefulness of average cost-effective ratios.平均成本效益比率的效用。
Health Econ. 1997 Sep-Oct;6(5):497-504. doi: 10.1002/(sici)1099-1050(199709)6:5<497::aid-hec298>3.0.co;2-v.
9
Confidence intervals for cost-effectiveness ratios: a comparison of four methods.成本效益比的置信区间:四种方法的比较
Health Econ. 1997 May-Jun;6(3):243-52. doi: 10.1002/(sici)1099-1050(199705)6:3<243::aid-hec269>3.0.co;2-z.
10
Bootstrap confidence intervals for cost-effectiveness ratios: some simulation results.成本效益比的自助法置信区间:一些模拟结果。
Health Econ. 1998 Mar;7(2):143-7. doi: 10.1002/(sici)1099-1050(199803)7:2<143::aid-hec322>3.0.co;2-q.

引用本文的文献

1
Sequential Therapies and the Cost-Effectiveness of Treating Metastatic Colon Cancer Patients.序贯疗法与转移性结直肠癌患者治疗的成本效益
J Manag Care Spec Pharm. 2016 Jun;22(6):628-39. doi: 10.18553/jmcp.2016.22.6.628.
2
Cost-effectiveness acceptability curves revisited.重新审视成本效益可接受性曲线。
Pharmacoeconomics. 2013 Feb;31(2):93-100. doi: 10.1007/s40273-012-0011-8.
3
Sample size determination for cost-effectiveness trials.成本效益试验的样本量确定。
Pharmacoeconomics. 2011 Nov;29(11):933-49. doi: 10.2165/11587130-000000000-00000.
4
Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies.在经济评估研究中使用净效益方法分析不确定性的优势。
Pharmacoeconomics. 2003;21(1):39-48. doi: 10.2165/00019053-200321010-00003.
5
The probability of cost-effectiveness.成本效益的概率。
BMC Med Res Methodol. 2002;2:5. doi: 10.1186/1471-2288-2-5. Epub 2002 Mar 11.
6
Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: a stochastic economic evaluation.他莫昔芬联合化疗与单纯他莫昔芬作为早期乳腺癌绝经后淋巴结阳性女性辅助治疗的随机经济学评估。
Pharmacoeconomics. 2002;20(2):119-37. doi: 10.2165/00019053-200220020-00005.
7
Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio.成本效益可接受性曲线和成本效益比的推断。
Pharmacoeconomics. 2000 Apr;17(4):339-49. doi: 10.2165/00019053-200017040-00004.
8
Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease.奥美拉唑和雷尼替丁间歇治疗有症状的胃食管反流病的成本效益
Pharmacoeconomics. 1999 Nov;16(5 Pt 1):483-97. doi: 10.2165/00019053-199916050-00006.
9
Handling uncertainty in economic evaluations of healthcare interventions.应对医疗保健干预措施经济评估中的不确定性。
BMJ. 1999 Sep 4;319(7210):635-8. doi: 10.1136/bmj.319.7210.635.
10
Use of confidence intervals in health economic studies.
Pharmacoeconomics. 1996 Oct;10(4):432-3. doi: 10.2165/00019053-199610040-00010.